Optimization and Evaluation of Cannabis-Based Magistral Formulations: A Path to Personalized Therapy.

IF 4.8 3区 医学 Q2 CHEMISTRY, MEDICINAL Pharmaceuticals Pub Date : 2025-01-09 DOI:10.3390/ph18010073
Bożena Grimling, Magdalena Fast, Magdalena Okoniewska, Artur Owczarek, Bożena Karolewicz
{"title":"Optimization and Evaluation of <i>Cannabis</i>-Based Magistral Formulations: A Path to Personalized Therapy.","authors":"Bożena Grimling, Magdalena Fast, Magdalena Okoniewska, Artur Owczarek, Bożena Karolewicz","doi":"10.3390/ph18010073","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The official implementation of pharmaceutical-grade cannabis raw materials for medicinal use has permitted doctors to prescribe and pharmacists to prepare cannabis-based formulations. The objective of the pharmaceutical development and manufacturing process optimization work was to propose a suppository formulation containing doses of 25 mg and 50 mg of tetra-hydrocannabinol (∆-9-THC) as an alternative to existing inhalable or orally administered formulations. The formulation could be used for rectal or vaginal administration, thereby providing dosage control in the treatment of endometriosis and other conditions involving pain. In this study, two substrates from suppositories with standardized <i>Cannabis extractum normatum</i> (CEX) were used: cocoa butter and Witepsol<sup>®</sup> H15.</p><p><strong>Materials and methods: </strong>The long-term stability of CEX was investigated over a period of up to 24 months. The concentrations of ∆-9-THC, cannabidiol (CBD), and cannabinol (CBN) were determined using an HPLC method. Furthermore, the water content of the extract, the ethanol residue, and the microbiological purity were determined. The pharmaceutical properties of CEX-incorporated suppositories, namely content uniformity, hardness, softening time, total deformation time, disintegration time, and the release profile of ∆-9-THC, CBD, and CBN, were evaluated in order to develop optimal preparation procedures for pharmacists.</p><p><strong>Results and discussion: </strong>Following a 24-month stability study on CEX, no significant alterations in component content were observed beyond the specified requirements. The disintegration time, total deformation time, and hardness of the suppositories based on Witepsol<sup>®</sup> H15 with CEX were found to be longer and higher, respectively, than those of suppositories formulated with cocoa butter. In vitro studies demonstrated that suppositories prepared with Witepsol<sup>®</sup> H15 exhibited superior release of ∆-9-THC compared to those prepared with cocoa butter.</p><p><strong>Conclusions: </strong>We suggest that pharmacists making prescription drugs in a pharmacy setting in the form of medical marijuana suppositories will receive a better release profile of the drug by choosing Witepsol® H15 as a substrate.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 1","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768162/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18010073","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The official implementation of pharmaceutical-grade cannabis raw materials for medicinal use has permitted doctors to prescribe and pharmacists to prepare cannabis-based formulations. The objective of the pharmaceutical development and manufacturing process optimization work was to propose a suppository formulation containing doses of 25 mg and 50 mg of tetra-hydrocannabinol (∆-9-THC) as an alternative to existing inhalable or orally administered formulations. The formulation could be used for rectal or vaginal administration, thereby providing dosage control in the treatment of endometriosis and other conditions involving pain. In this study, two substrates from suppositories with standardized Cannabis extractum normatum (CEX) were used: cocoa butter and Witepsol® H15.

Materials and methods: The long-term stability of CEX was investigated over a period of up to 24 months. The concentrations of ∆-9-THC, cannabidiol (CBD), and cannabinol (CBN) were determined using an HPLC method. Furthermore, the water content of the extract, the ethanol residue, and the microbiological purity were determined. The pharmaceutical properties of CEX-incorporated suppositories, namely content uniformity, hardness, softening time, total deformation time, disintegration time, and the release profile of ∆-9-THC, CBD, and CBN, were evaluated in order to develop optimal preparation procedures for pharmacists.

Results and discussion: Following a 24-month stability study on CEX, no significant alterations in component content were observed beyond the specified requirements. The disintegration time, total deformation time, and hardness of the suppositories based on Witepsol® H15 with CEX were found to be longer and higher, respectively, than those of suppositories formulated with cocoa butter. In vitro studies demonstrated that suppositories prepared with Witepsol® H15 exhibited superior release of ∆-9-THC compared to those prepared with cocoa butter.

Conclusions: We suggest that pharmacists making prescription drugs in a pharmacy setting in the form of medical marijuana suppositories will receive a better release profile of the drug by choosing Witepsol® H15 as a substrate.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
以大麻为基础的裁判配方的优化和评价:个性化治疗之路。
导言:药用级大麻原料的正式实施允许医生开处方和药剂师制备基于大麻的配方。药物开发和生产工艺优化工作的目标是提出一种含有25毫克和50毫克四氢大麻酚(∆-9-THC)剂量的栓剂配方,作为现有可吸入或口服制剂的替代方案。该制剂可用于直肠或阴道给药,从而为治疗子宫内膜异位症和其他涉及疼痛的疾病提供剂量控制。在本研究中,使用了两种来自标准大麻提取物(CEX)栓剂的底物:可可脂和Witepsol®H15。材料和方法:在长达24个月的时间里,研究了CEX的长期稳定性。采用高效液相色谱法测定∆-9-THC、大麻二酚(CBD)、大麻酚(CBN)的浓度。进一步测定了提取液的含水量、乙醇残留量和微生物纯度。通过对cex栓剂的含量均匀度、硬度、软化时间、总变形时间、崩解时间以及∆-9-THC、CBD、CBN的释放特性进行评价,为药师制定最佳制备工艺。结果和讨论:经过24个月的CEX稳定性研究,未观察到超出规定要求的组分含量的显著变化。用CEX配制的Witepsol®H15栓剂的崩解时间、总变形时间和硬度分别比用可可脂配制的栓剂长和高。体外研究表明,与用可可脂制备的栓剂相比,用Witepsol®H15制备的栓剂释放∆-9-THC的效果更好。结论:选用Witepsol®H15作为底物,药剂师在药房以医用大麻栓剂的形式制作处方药,可以获得更好的药物释放谱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmaceuticals
Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍: Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
期刊最新文献
Hepatotoxicity Assessment of Anshenbunao Syrup by Multi-Component Quantification In Vivo/In Vitro and Cell Biological Evaluations Preliminary Data Regarding the Potential of Oxytocin to Modulate Aggressive Behaviour in a VPA-Based Animal Model of Autism Spectrum Disorder. A Comparative Evaluation of the Therapeutic Effects of Adenosine Triphosphate, Coenzyme Q10, Pyridoxine, and Thiamine Pyrophosphate in a Linezolid-Induced Peripheral Neuropathic Pain Model in Rats. Novel Propofol Analogs: Design, Synthesis and Evaluation of Dihydrobenzofuran Derivatives as General Anesthetics. Adaptogenic and Neuroprotective Effects of the Thai Herbal Formula AYW-KK-04 Against Chronic Stress-Induced Cognitive Impairment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1